Login to Your Account



Pearl's LAMA/LABA Combo Inhaler Enters Phase III Trial

By Catherine Shaffer
Staff Writer

Wednesday, May 15, 2013
Pearl Therapeutics Inc. launched its much-anticipated Phase III (PINNACLE) trial of PT003, a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered by pressurized hydrofluoroalkane, in chronic obstructive pulmonary disease (COPD).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription